- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02370654
Chen-style Tai Chi in Pulmonary Rehabilitation for Chronic Obstructive Pulmonary Disease
April 22, 2018 updated by: Louis Gendron, Laval University
This study will evaluate the effects of Chen-style Tai Chi compared to conventional exercise in pulmonary rehabilitation for COPD patients.
Half of participants will receive the Chen-style Tai Chi intervention, while the other half will receive the conventional exercise intervention.
Both groups will receive the same eduction and support during pulmonary rehabilitation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
44
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Quebec, Canada, G1V 4G5
- Institut Universitaire de cardiologie et de pneumologie de Quebec
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- FEV1 between 30 and 80% of the predicted normal values
- FEV1/FVC ratio < 70%
Exclusion Criteria:
- Patients with very severe COPD (GOLD IV);
- Patients that had a COPD exacerbations within the preceding 2 weeks of the baseline assessments;
- Significant hypoxemia at rest or during exercise (SpO2 <85%);
- Already following a rehabilitation program;
- Have physical limitations that compromises participation to a Tai chi and a conventional exercise program
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Tai Chi
12 week Tai chi intervention, 3 sessions per week, 90 minutes per session
|
|
|
Active Comparator: Conventional exercise
12 week conventional exercise intervention, 3 sessions per week, 90 minutes per session
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline dyspnea at 12 weeks
Time Frame: Baseline, 12 weeks
|
Dyspnea will be assessed using the chronic respiratory questionnaire (CRQ)
|
Baseline, 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline lung function at week 12 (Spirometry and whole-body plethysmography)
Time Frame: Baseline, 12 weeks
|
Spirometry and whole-body plethysmography will be used for baseline and post-training (12 weeks) lung function testing.
|
Baseline, 12 weeks
|
|
Change from baseline walking distance at 12 weeks (distance walked during the six-minute walk test)
Time Frame: Baseline, 12 weeks
|
The distance walked during the six-minute walk test will be used to evaluate the functional exercise capacity of all participants at baseline and post-rehabilitation.
|
Baseline, 12 weeks
|
|
Change from baseline exercise capacity at 12 weeks(Endurance time during a constant work rate bicycle ergometry exercise test)
Time Frame: Baseline, 12 weeks
|
Endurance time during a constant work rate bicycle ergometry exercise test will be used to evaluate the exercise capacity of all participants at baseline and post-rehabilitation.
|
Baseline, 12 weeks
|
|
Change from baseline isokinetic quadriceps muscle function at 12 weeks
Time Frame: Baseline, 12 weeks
|
Voluntary isokinetic quadriceps muscle function will be determined by quantification of force, endurance, and fatigability of the dominant quadriceps during a series of 30 repetitions at an angular velocity of 90°/s of a knee extension test.
|
Baseline, 12 weeks
|
|
Change from baseline isometric quadriceps muscle strength at 12 weeks (force of the dominant quadriceps will be measured during a single magnetic stimulation of the femoral nerve)
Time Frame: Baseline, 12 weeks
|
The force of the dominant quadriceps will be measured during a single magnetic stimulation of the femoral nerve (Twitch force of the quadriceps [Twq]) and during a maximum voluntary contraction (MVC).
|
Baseline, 12 weeks
|
|
Change from baseline physical activity at 12 weeks (participants will be equipped with a physical activity monitor)
Time Frame: Baseline, 12 weeks
|
To monitor physical activity, participants will be equipped with a physical activity monitor.
The device will monitor the daily energy expenditure, the duration of physical activities above the pre-determined intensity level (Metabolic Equivalent of Task (MET) >3), and also the total daily number of steps.
|
Baseline, 12 weeks
|
|
Change from baseline quality of life (QoL) at 12 weeks
Time Frame: Baseline, 12 weeks
|
In addition to dyspnea (primary outcome), the CRQ will be used also to measure other physical-functional limitations due to COPD with questions related to fatigue and energy levels.
|
Baseline, 12 weeks
|
|
Change from baseline health status at 12 weeks (determined with the COPD Assessment test (CAT).
Time Frame: Baseline, 12 weeks
|
Impact of COPD on a person's life will be determined with the COPD Assessment test (CAT).
|
Baseline, 12 weeks
|
|
Change from baseline balance (Berg Balance Test (BBT) at 12 weeks
Time Frame: Baseline, 12 weeks
|
The Berg Balance Test (BBT) will be used to evaluate the effect of the interventions on patient's balance.
|
Baseline, 12 weeks
|
|
Change from baseline of composite serum and plasma biomarkers at 12 weeks
Time Frame: Baseline, 12 weeks
|
During the baseline assessment and after the rehabilitation program, blood samples from patients will be taken in order to investigate the effect of the interventions on different biomarkers related to systemic inflammation.
|
Baseline, 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: François Maltais, MD, PhD, Francois.Maltais@fmed.ulaval.ca
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2014
Primary Completion (Actual)
July 1, 2017
Study Completion (Actual)
July 1, 2017
Study Registration Dates
First Submitted
February 11, 2015
First Submitted That Met QC Criteria
February 18, 2015
First Posted (Estimate)
February 25, 2015
Study Record Updates
Last Update Posted (Actual)
April 24, 2018
Last Update Submitted That Met QC Criteria
April 22, 2018
Last Verified
April 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TCCOPD CER21009
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.